Ocena niezależnych czynników ryzyka konwersji w psychozę w grupie osób z wysokim ryzykiem rozwoju zaburzeń psychotycznych

• Authors: Marta Gawłowska , Jolanta Rabe-Jabłońska , Tomasz Pawełczyk , Agnieszka Pawełczyk

Title variants

EN

Assessment of independent risk factors of conversion into psychosis in the ultra-high risk state group of patients

• Languages of publication: EN PL

Abstracts

EN

Background: The aim of this study was the independent psychosis risk factors assessment in a group of subjects fulfilling the criteria of at risk mental state, under specialist outpatient psychiatric care. Participants: Seventy-one patients – 33 women and 38 men, were involved into this study, aged on average 17.34, all under psychiatric care. The patients were recruited into the study in the sequence of their outpatient clinic admission. The criterion to be included into the study was the diagnosis of ultra-high risk state (UHRS) – defined according to the Australian research group principles. Subsequently, the patients were divided into subgroups according to the clinical features of their mental state. Method: The author’s demographic questionnaire was applied in the study. Information regarding the family history of psychosis was obtained from patients and/or their relatives or carers. The patients’ mental state was assessed monthly – according to the presence of psychotic symptoms, change of their incidence and duration, presence of depressive symptoms or aggressive behaviour (measured by a three-level scale). On the basis of the obtained information, we evaluated: 1) conversion into psychosis time – measured from diagnosing of UHRS to the development of full-symptom psychosis, 2) therapeutic methods used (psychotherapy, pharmacotherapy or both), 3) use of psychoactive substances after being diagnosed with UHRS, 4) presence of serious life stressors (the patients’ subjective estimation) – during the six-month period preceding the conversion into psychosis. Results: 1) In the UHRS group of patients, staying under professional outpatient psychiatric care, the use of marijuana was an independent risk factor of conversion into psychosis. 2) In the investigated group of patients with at risk mental state we did not find any correlation between modulating factors (including: therapeutic methods used, depressive symptoms, aggression or clinical features of UHRS patients’ subgroups or duration of staying under professional psychiatric care) and controlled period without conversion into psychosis.

PL

Założenia i cel pracy: Celem pracy było poszukiwanie niezależnych czynników ryzyka konwersji w psychozę w grupie osób spełniających kryteria ryzykownego stanu psychicznego i pozostających pod ambulatoryjną opieką lekarską. Grupa badana: Do udziału w badaniu zakwalifikowano 71 pacjentów – 33 kobiety i 38 mężczyzn, ze średnią wieku 17,34 roku, pozostających w opiece ambulatoryjnej. Pacjenci byli kolejno włączani do badania w porządku odpowiadającym chronologii zgłaszania się do poradni. Kryterium włączenia do badania było stwierdzenie obecności stanu ryzyka rozwoju psychozy (ultra-high risk state, UHRS), definiowanego według zasad zaproponowanych przez zespół australijskich badaczy. Pacjenci byli następnie kwalifikowani do jednej z podgrup UHRS – w zależności od obserwowanego obrazu klinicznego. Metoda: W badaniu wykorzystano autorski kwestionariusz do zbierania danych demograficznych. Dane o obciążeniu rodzinnym psychozą uzyskano na podstawie wywiadu z pacjentem i/lub jego opiekunami. Od momentu włączenia uczestników do grupy UHRS co miesiąc oceniano ich stan psychiczny pod kątem wystąpienia objawów psychotycznych, zmiany czasu ich trwania i częstości występowania, obecności objawów depresyjnych i agresji (nasilenie oceniano w trójstopniowej skali). Na podstawie uzyskanej dokumentacji ustalono: 1) czas przejścia w psychozę – obliczany od momentu stwierdzenia UHRS do momentu wystąpienia objawów pełnej psychozy (z dokładnością do 1 miesiąca), 2) stosowane metody terapeutyczne (psychoterapia, farmakoterapia, obie formy), 3) używanie substancji psychoaktywnych po stwierdzeniu UHRS, 4) występowanie poważnych sytuacji stresujących (wg subiektywnej oceny badanych) w ostatnim półroczu przed konwersją w psychozę. Wnioski: 1) Stwierdzono, że w grupie badanych spełniających kryteria stanu wysokiego ryzyka rozwoju psychozy (UHRS) i pozostających pod ambulatoryjną opieką lekarską używanie marihuany było niezależnym czynnikiem ryzyka konwersji w psychozę. 2) W badanej populacji pacjentów z grupy ryzyka rozwoju psychozy nie wykazano istotnego związku pomiędzy zastosowanymi czynnikami modulującymi (w tym: stosowanymi procedurami terapeutycznymi, nasileniem objawów depresyjnych, agresji oraz obrazem klinicznym definiowanym zgodnie z kryteriami wyróżniania podgrup UHRS) z czasem pozostawania w opiece psychiatrycznej bez konwersji w psychozę.

Keywords

EN

czynnikimodulujące; czynniki ryzyka konwersji w psychozę; marihuana; modulating factors; psychosis; psychoza; risk factors of conversion into psychosis; stan wysokiego ryzyka rozwoju psychozy; ultra-high risk state

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Communications
• Journal: Psychiatria i Psychologia Kliniczna
• Year: 2010
• Volume: 10
• Issue: 4
• Pages: 254-266

Contributors

author

Marta Gawłowska

• Klinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

author

Jolanta Rabe-Jabłońska

• vKlinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

author

Tomasz Pawełczyk

• Klinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

author

Agnieszka Pawełczyk

• Klinika Zaburzeń Afektywnych i Psychotycznych, Katedra Psychiatrii Uniwersytetu Medycznego w Łodzi. Kierownik: prof. dr hab. n. med. Jolanta Rabe-Jabłońska

References

• 1. Done D.J., Johnstone E.C., Frith C.D. i wsp.: Complications of pregnancy and delivery in relation to psychosis in adult life: data from the British perinatal mortality survey sample. BMJ 1991; 302: 1576-1580.
• 2. Fatemi S.H., Folsom T.D.: The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009; 35: 528-548.
• 3. Hulshoff Pol H.E., Schnack H.G., Bertens M.G. i wsp.: Volume changes in gray matter in patients with schizophrenia. Am. J. Psychiatry 2002; 159: 244-250.
• 4. Kupfer D.J.: Proposed Draft Revisions to DSM Disorders and Criteria 2010. Adres: http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=412.
• 5. M0ller P., Husby R.: The initial prodrome in schizophrenia: searching for naturalistic core dimensions of experience and behavior. Schizophr. Bull. 2000; 26: 217-232.
• 6. Remington G., Shammi C.: The use of pharmacotherapy in the prodrome of schizophrenia. CNS Spectr. 2004; 9: 579-586.
• 7. Ruhrmann S., Schultze-Lutter F., Klosterkotter J.: Probably at-risk, but certainly ill - advocating the introduction of a psychosis spectrum disorder in DSM-V Schizophr. Res. 2010; 120: 23-37.
• 8. Suzuki M., Nohara S., Hagino H. i wsp.: Regional changes in brain gray and white matter in patients with schizophrenia demonstrated with voxel-based analysis of MRI. Schizophr. Res. 2002; 55: 41-54.
• 9. Thompson P.M., Vidal C., Giedd J.N. i wsp.: Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc. Natl Acad. Sci. USA 2001; 98: 11650-11655.
• 10. Warner R.: Problems with early and very early intervention in psychosis. Br. J. Psychiatry Suppl. 2005; 48: s104-s107.
• 11. Geddes J.R., Lawrie S.M.: Obstetric complications and schizophrenia: a meta-analysis. Br. J. Psychiatry 1995; 167: 786-793.
• 12. Klosterkotter J., Hellmich M., Steinmeyer E.M., Schultze-Lutter F.: Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry 2001; 58: 158-164.
• 13. Peterson D.R.: The ethics of research into schizophrenia prevention: a carer’s perspective. Aust. N. Z. J. Psychiatry 2000: 34 supl.: S201-S203.
• 14. Ruhrmann S., Schultze-Lutter F., Salokangas R.K. i wsp.: Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch. Gen. Psychiatry 2010; 67: 241-251.
• 15. Semple D.M., McIntosh A.M., Lawrie S.M.: Cannabis as a risk factor for psychosis: systematic review. J. Psychopharmacol. 2005; 19: 187-194.
• 16. Fuchs J., Steinert T.: Duration of untreated psychosis (DUP): an useful predictor of outcome in schizophrenia? Fortschr. Neurol. Psychiatr. 2004; 72: 79-87.
• 17. Klosterkotter J.: Indicated prevention of schizophrenia. Dtsch. Arztebl. Int. 2008; 105: 532-539.
• 18. Verdoux H., Geddes J.R., Takei N. i wsp.: Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am. J. Psychiatry 1997; 154: 1220-1227.
• 19. Verdoux H., Cougnard A.: The early detection and treatment controversy in schizophrenia research. Curr. Opin. Psychiatry 2003; 16: 175-179.
• 20. Chung Y.S., Kang D.H., Shin N.Y. i wsp.: Deficit of theory of mind in individuals at ultra-high-risk for schizophrenia. Schizophr. Res. 2008; 99: 111-118.
• 21. Correll C.U., Hauser M., Auther A.M., Cornblatt B.A.: Research in people with psychosis risk syndrome: a review of the current evidence and future directions. J. Child Psychol. Psychiatry 2010; 51: 390-431.
• 22. Klaassen M.C., Nieman D.H., Becker H.E., Linszen D.H.: Is there any point in detecting high risk factors prior to a first psychosis? Tijdschr. Psychiatr. 2006; 48: 467-476.
• 23. McGorry P.D., Killackey E.J.: Early intervention in psychosis: a new evidence based paradigm. Epidemiol. Psichiatr. Soc. 2002; 11: 237-247.
• 24. McGorry PD., Nelson B., Amminger G.P. i wsp.: Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J. Clin. Psychiatry 2009; 70: 1206-1212.
• 25. Murray R.M.: Neurodevelopmental schizophrenia: the rediscovery of dementia praecox. Br. J. Psychiatry Suppl. 1994; (25): 6-12.
• 26. Nakamura M., Salisbury D.F., Hirayasu Y. i wsp.: Neocortical gray matter volume in first-episode schizophrenia and first-episode affective psychosis: a cross-sectional and longitudinal MRI study. Biol. Psychiatry 2007; 62: 773-783.
• 27. Warner R.: The prevention of schizophrenia: what interventions are safe and effective? Schizophr. Bull. 2001; 27: 551-562.
• 28. Wright P., Takei N., Rifkin L., Murray R.M.: Maternal influenza, obstetric complications, and schizophrenia. Am. J. Psychiatry 1995; 152: 1714-1720.
• 29. van Os J., Bak M., Hanssen M. i wsp.: Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002; 156: 319-327.
• 30. Yung A.R., Phillips L.J., Yuen H.P., McGorry P.D.: Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 2004; 67: 131-142.
• 31. Yung A.R., Yuen H.P, McGorry P.D. i wsp.: Mapping the onset of psychosis: the Comprehensive Assessment of At-Risk Mental States. Aust. N. Z. J. Psychiatry 2005; 39: 964-971.
• 32. McGorry P.D., Edwards J., Mihalopoulos C. i wsp.: EPPIC: an evolving system of early detection and optimal management. Schizophr. Bull. 1996; 22: 305-326.
• 33. McGorry P.D., Yung A., Phillips L.: Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr. Res. 2001; 51: 17-29.
• 34. Corcoran C.M., First M.B., Cornblatt B.: The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr. Res. 2010; 120: 16-22.
• 35. Kotlicka-Antczak M., Gmitrowicz A., Sobów T.M., Rabe-Jabłońska J.: Obstetric complications and Apgar score in early-onset schizophrenic patients with prominent positive and prominent negative symptoms. J. Psychiatr. Res. 2001; 35: 249-257.
• 36. Lin H.C., Lee H.C., Tang C.H., Chen Y.H.: The relation between maternal schizophrenia and low birth weight is modified by paternal age. Can. J. Psychiatry 2010; 55: 377-385.
• 37. Morrison A.P., Bentall R.P., French P. i wsp.: Randomised controlled trial of early detection and cognitive therapy for preventing transition to psychosis in high-risk individuals. Study design and interim analysis of transition rate and psychological risk factors. Br. J. Psychiatry Suppl. 2002; 43: s78-s84.
• 38. Morrison A.P., French P., Parker S. i wsp.: Three-year follow-up of a randomized controlled trial of cognitive therapy for the prevention of psychosis in people at ultrahigh risk. Schizophr. Bull. 2007; 33: 682-687.
• 39. Wilke M., Kaufmann C., Grabner A. i wsp.: Gray matter-changes and correlates of disease severity in schizophrenia: a statistical parametric mapping study. Neuroimage 2001; 13: 814-824.
• 40. Wood S.J., Pantelis C., Proffitt T. i wsp.: Spatial working memory ability is a marker of risk-for-psychosis. Psychol. Med. 2003; 33: 1239-1247.
• 41. Velthorst E., Nieman D.H., Becker H.E. i wsp.: Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis. Schizophr. Res. 2009; 109: 60-65.
• 42. Yang L.H., Wonpat-Borja A.J., Opler M.G., Corcoran C.M.: Potential stigma associated with inclusion of the psychosis risk syndrome in the DSM-V: an empirical question. Schizophr. Res. 2010; 120: 42-48.
• 43. Yung A.R., Nelson B., Thompson A.D., Wood S.J.: Should a “Risk Syndrome for Psychosis” be included in the DSMV? Schizophr. Res. 2010; 120: 7-15.
• 44. Addington J., Van Mastrigt S., Addington D.: Duration of untreated psychosis: impact on 2-year outcome. Psychol. Med. 2004; 34: 277-284.
• 45. Beiser M., Erickson D., Fleming J.A., Iacono WG.: Establishing the onset of psychotic illness. Am. J. Psychiatry 1993; 150: 1349-1354.
• 46. Carr V, Halpin S., Lau N. i wsp.: A risk factor screening and assessment protocol for schizophrenia and related psychosis. Aust. N. Z. J. Psychiatry 2000; 34 supl.: S170-S180.
• 47. Birchwood M., Fiorillo A.: The critical period for early intervention. Am. J. Psychiatr. Rehabil. 2000; 4: 182-198.
• 48. Cannon T.D., Cadenhead K., Cornblatt B. i wsp.: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 2008; 65: 28-37.
• 49. Drake R.J., Haley C.J., Akhtar S., Lewis S.W: Causes and consequences of duration of untreated psychosis in schizophrenia. Br. J. Psychiatry 2000; 177: 511-515.
• 50. Ferdinand R.F., Sondeijker F., van der Ende J. i wsp.: Cannabis use predicts future psychotic symptoms, and vice versa. Addiction 2005; 100: 612-618.
• 51. Killackey E., Yung A.R.: Effectiveness of early intervention in psychosis. Curr. Opin. Psychiatry 2007; 20: 121-125.
• 52. McGlashan T.H., Zipursky R.B., Perkins D. i wsp.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am. J. Psychiatry 2006; 163: 790-799.
• 53. Cahn W, Rais M., Stigter F.P. i wsp.: Psychosis and brain volume changes during the first five years of schizophrenia. Eur. Neuropsychopharmacol. 2009; 19: 147-151.
• 54. French P., Shryane N., Bentall R.P. i wsp.: Effects of cognitive therapy on the longitudinal development of psychotic experiences in people at high risk of developing psychosis. Br. J. Psychiatry Suppl. 2007; 51: s82-s87.
• 55. Hafner H., Maurer K., Ruhrmann S. i wsp.: Early detection and secondary prevention of psychosis: facts and visions. Eur. Arch. Psychiatry Clin. Neurosci. 2004; 254: 117-128.
• 56. Harrigan S.M., McGorry P.D., Krstev H.: Does treatment delay in first-episode psychosis really matter? Psychol. Med. 2003; 33: 97-110.
• 57. Morrison A.P., French P., Walford L. i wsp.: Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br. J. Psychiatry 2004; 185: 291-297.
• 58. Ruhrmann S., Schultze-Lutter F., Klosterkotter J.: Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry 2003; 36 supl. 3: S162-S167.
• 59. Simon A.E., Cattapan-Ludewig K., Zmilacher S. i wsp.: Cognitive functioning in the schizophrenia prodrome. Schizophr. Bull. 2007; 33: 761-771.
• 60. Eastvold A.D., Heaton R.K., Cadenhead K.S.: Neurocognitive deficits in the (putative) prodrome and first episode of psychosis. Schizophr. Res. 2007; 93: 266-277.
• 61. Phillips L.J., Curry C., Yung A.R. i wsp.: Cannabis use is not associated with the development of psychosis in an ‘ultra’ high-risk group. Aust. N. Z. J. Psychiatry 2002; 36: 800-806.
• 62. Sullivan E.V, Shear P.K., Lim K.O. i wsp.: Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. Biol. Psychiatry 1996; 39: 234-240.
• 63. Lemos-Giraldez S., Vallina-Fernandez O., Fernandez-Iglesias P i wsp.: Symptomatic and functional outcome in youth at ultra-high risk for psychosis: a longitudinal study. Schizophr. Res. 2009; 115: 121-129.
• 64. French P., Morrison A.P.: Early Detection and Cognitive Therapy for People at High Risk of Developing Psychosis: A Treatment Approach. John Wiley & Sons, Ltd., Chichester 2004.
• 65. Kristensen K., Cadenhead K.S.: Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007; 151: 151-154.
• 66. Bechdolf A., Wagner M., Veith V i wsp.: Randomized controlled multicentre trial of cognitive behaviour therapy in the early initial prodromal state: effects on social adjustment post treatment. Early Interv. Psychiatry 2007; 1: 71-78.
• 67. Jones P.B., Rantakallio P., Hartikainen A.L. i wsp.: Schizophrenia as a long-term outcome of pregnancy, delivery, and perinatal complications: a 28-year follow-up of the 1966 north Finland general population birth cohort. Am. J. Psychiatry 1998; 155: 355-364.
• 68. Le Bec P.Y., Fatseas M., Denis C. i wsp.: Cannabis and psychosis: search of a causal link through a critical and systematic review. Encephale 2009; 35: 377-385.
• 69. McGorry P.D., Yung A.R., Phillips L.J. i wsp.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch. Gen. Psychiatry 2002; 59: 921-928.
• 70. McGrath J., Welham J., Scott J. i wsp.: Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 2010; 67: 440-447.
• 71. Miller T.J., McGlashan T.H., Rosen J.L. i wsp.: Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am. J. Psychiatry 2002; 159: 863-865.
• 72. Yung A., Phillips L., McGorry P.D.: Treating Schizophrenia in the Prodromal Phase. Taylor & Francis, London 2004.
• 73. Bechdolf A., Veith V, Schwarzer D. i wsp.: Cognitive-behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Res. 2005: 136: 251-255.
• 74. Christodoulides T., Dudley R., Brown S. i wsp.: Cognitive behaviour therapy in patients with schizophrenia who are not prescribed antipsychotic medication: a case series. Psychol. Psychother. 2008; 81: 199-207.
• 75. van Os J., Selten J.P.: Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. Br. J. Psychiatry 1998; 172: 324-326.

• Document Type: article